

INDICATION	TRIAL	PI	KEY INFORMATION
SLE	M23-699 Phase III Upadacitinib	Assoc. Prof. Alberta Hoi	moderate - severe active SLE 52 week - Study 1 & 2 (+open label study 3 & 4 - 12mth-3yrs) JAK Inhibitor <63 years old <b>Actively recruiting -closing soon</b>
SLE IIM RA SSc	BMS IM060-0001 Phase I BMS 986515	Professor Eric Morand	open label, allogeneic IP-CD-19 targeted IP-sev. refractory autoimmune-4 arms <b>Commencing @March 2026</b>
Sjogren's	ARGX 113-2306 Phase III Efgartigimod PH20 SC	Assoc. Prof. Alberta Hoi	Mod-sev. pSjD (clinESSDAI $\geq$ 6) double-blind 1:1 to wk 48, OLE 48 weeks binds with IgG resulting in IgG degradation <b>Open to recruitment</b>
ACLE SCLE DLE	Phase III	Assoc. Prof. Alberta Hoi	details to come  <b>Commencing March/April 2026</b>
RA SLE	Phase I	Professor Eric Morand	details to come-exciting new T Cell engager  <b>Commencing March/April 2026</b>